Mga Batayang Estadistika
| LEI | 549300QM1VCWH8KT0S21 |
| CIK | 921114 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Armata Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
Exhibit 4.12 Form of Indenture ARMATA PHARMACEUTICALS, INC. as ISSUER and As INDENTURE TRUSTEE INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 ARTICLE |
|
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025 As filed with the Securities and Exchange Commission on August 13, 2025 Registration No. |
|
| August 13, 2025 |
Calculation of Filing Fee Tables S-3 Armata Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwar |
|
| August 13, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Armata Pharmaceuticals, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.01 per share Other 1,809,153 $ 2.50 $ 4,522,882.50 0.0001531 $ 692.45 2 Equit |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 91-1549568 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5005 McConnell Avenue Los Angeles, CA 90066 (Address of P |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 ARMATA PHARMACEUTICAL |
|
| August 12, 2025 |
Credit and Security Agreement, dated August 11, 2025. Credit and Security Agreement Dated as of August 11, 2025 by and among ARMATA PHARMACEUTICALS, INC. |
|
| August 12, 2025 |
Exhibit 99.1 Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES, CA, August 12, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stag |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025 ARMATA PHARMACEUTICALS, INC. |
|
| June 13, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2025 ARMATA PHARMACEUTICALS, INC. |
|
| May 19, 2025 |
Exhibit 99.1 Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available an |
|
| May 19, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2025 ARMATA PHARMACEUTICALS, INC. |
|
| May 19, 2025 |
Exhibit 99.2 Corporate Presentation May 19, 2025 NYSE American: ARMP 2 This presentation contains “forward-looking” statements that involve risks, uncertainties and assumptions. If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of hi |
|
| May 14, 2025 |
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update Exhibit 99.1 Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update LOS ANGELES, CA, May 14, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2025 ARMATA PHARMACEUTICALS, INC. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 ARMATA PHARMACEUTICA |
|
| May 1, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2025 ARMATA PHARMACEUTICALS, INC. |
|
| May 1, 2025 |
Exhibit 99.1 Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy tri |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2025 ARMATA PHARMACEUTICALS, INC. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-375 |
|
| March 21, 2025 |
Exhibit 10.38 Armata Pharmaceuticals, Inc. 5005 McConnell Ave Los Angeles, California 90066 June 1, 2024 Dear Pierre: This letter agreement (this “Agreement”) is intended to confirm our mutual agreement with respect to your continued employment with Armata Pharmaceuticals, Inc. (the “Company”) from and after the date hereof. 1.Position. You agree to serve as the Company’s Chief Business Officer, r |
|
| March 21, 2025 |
Exhibit 19.1 Armata Pharmaceuticals, Inc. AMENDED AND RESTATED INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities Effective as of December 16, 2024 And As Amended Through December 16, 2024 TABLE OF CONTENTS Page INTRODUCTION1 Legal prohibitions on insider trading1 Detection and prosecution of insider trading1 Penalties for violation of insider trading laws |
|
| March 21, 2025 |
Exhibit 97 Execution Copy ARMATA PHARMACEUTICALS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1.Purpose. The purpose of this Policy is to describe the circumstances in which Executives will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. Each current and future Executive Officer shall be required to sign and return to the Compan |
|
| March 21, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 ARMATA PHARMACEUTICALS, INC. |
|
| March 21, 2025 |
Exhibit 21.1 Subsidiaries of Armata Pharmaceuticals, Inc. The following companies are direct or indirect wholly owned subsidiaries of Armata Pharmaceuticals, Inc.: Name Jurisdiction C3J Therapeutics, Inc. C3 Jian, LLC United States United States Biocontrol Limited United Kingdom AmpliPhi Australia Pty Ltd Australia Special Phage Holdings Pty Ltd Australia Special Phage Services Pty Ltd Australia |
|
| March 21, 2025 |
Description of the Company’s securities registered under Section 12 of the Exchange Act. Exhibit 4.9 DESCRIPTION OF COMMON STOCK The following description of our common stock, certain provisions of our articles of incorporation and bylaws, and certain provisions of Washington law are summaries. The following description is not complete and is subject to and qualified in its entirety by our articles of incorporation and bylaws. As of March 15, 2020, our articles of incorporation author |
|
| March 21, 2025 |
Exhibit 99.1 Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update LOS ANGELES, CA, March 20, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant |
|
| March 12, 2025 |
Exhibit 10.3 THIRD AMENDMENT TO CREDIT AND SECURITY AGREEMENT THIRD AMENDMENT TO CREDIT AND SECURITY AGREEMENT, dated as of March 12, 2025 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “Guarantors” and, together with the Borrower, the “Loan Parties”) an |
|
| March 12, 2025 |
Exhibit 99.1 Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva Proceeds to be used to continue to advance development of Armata’s phage product candidates LOS ANGELES, Calif., March 12, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity pathogen-spe |
|
| March 12, 2025 |
Exhibit 10.2 FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT, dated as of March 12, 2025 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “Guarantors” and, together with the Borrower, the “Loan Parties”) an |
|
| March 12, 2025 |
Exhibit 10.1 CREDIT AND SECURITY AGREEMENT Credit and Security Agreement, dated as of March 12, 2025, by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Subsidiary of the Borrower listed as a “Guarantor” on the signature pages hereto (together with each other Person that executes a joinder agreement and becomes a “Guarantor” hereunder or otherwise guarantees |
|
| March 12, 2025 |
Exhibit 10.4 FOURTH AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT FOURTH AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT, dated as of March 12, 2025 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “Guarantors” and, together |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2025 ARMATA PHARMACEUTICALS, INC. |
|
| December 19, 2024 |
Corporate Presentation December 19, 2024 NYSE American: ARMP Exhibit 99.2 Corporate Presentation December 19, 2024 NYSE American: ARMP 2 This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All statements other than state |
|
| December 19, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (C |
|
| December 19, 2024 |
Exhibit 99.1 Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile LOS ANGELES, Calif., D |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Co |
|
| December 4, 2024 |
Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this “Agreement”), originally delivered November 13, 2024, confirms the following understandings and agreements between Armata Pharmaceuticals, Inc. (the “Company”) and Mina Pastagia, M.D. (hereinafter referred to as “you” or “your”). In consideration of the promises set forth herein, you and the Company agree as |
|
| November 15, 2024 |
Exhibit 10.1 Execution Version SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT, dated as of November 12, 2024 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “Guarantors” and, together with the Borrower, |
|
| November 15, 2024 |
Exhibit 10.2 Execution Version THIRD AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT THIRD AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT, dated as of November 12, 2024 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “Guaran |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| November 14, 2024 |
Execution Version SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT EX-99.1 2 ef20038691ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Execution Version SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT, dated as of November 12, 2024 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “ |
|
| November 14, 2024 |
Execution Version THIRD AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT EX-99.2 3 ef20038691ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Execution Version THIRD AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT THIRD AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT, dated as of November 12, 2024 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Cred |
|
| November 14, 2024 |
ARMP / Armata Pharmaceuticals, Inc. / Innoviva, Inc. - SC 13D/A Activist Investment SC 13D/A 1 ef20038691sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-109 |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 ARMATA PHARMACEU |
|
| November 13, 2024 |
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update Exhibit 99.1 Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update LOS ANGELES, CA, November 13, 2024 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced f |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| November 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| November 12, 2024 |
Exhibit 99.1 Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025 LOS ANGELES, Calif., November 12, 2024 - Armata Pharmaceuticals, Inc. (NYSE American: |
|
| October 3, 2024 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AND RELEASE AGREEMENT This Confidential Separation and Release Agreement (this “Agreement”), originally delivered September 24, 2024, confirms the following understandings and agreements between Armata Pharmaceuticals, Inc. (the “Company”) and Richard Rychlik (hereinafter referred to as “you” or “your”). In consideration of the promises set forth herein, you an |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) ( |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2024 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) ( |
|
| August 26, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Com |
|
| August 26, 2024 |
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium Exhibit 99.2 Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium LOS ANGELES, Calif., August 26, 2024 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacteria |
|
| August 26, 2024 |
Exhibit 99.1 Phase 2 Clinical Trials Evaluating Multi-phage Candidates for the Treatment of Adults with Bacteremia due to Staphylococcus aureus (diSArm) and Chronic Respiratory Infections due to Pseudomonas aeruginosa (SWARM-P.a. & Tailwind) Mina Pastagia, MD, Stacey Kolar, PhD, Pierre Kyme, PhD, Thomas Feinberg, MS, Deborah Birx, MD Armata Pharmaceuticals, Inc., Los Angeles, California INTRODUCTI |
|
| August 26, 2024 |
Corporate Presentation August 26, 2024 NYSE American: ARMP Exhibit 99.3 Corporate Presentation August 26, 2024 NYSE American: ARMP 2 This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All statements other than stateme |
|
| August 15, 2024 |
Exhibit 10.1 Armata Pharmaceuticals, Inc. 5005 McConnell Ave. Los Angeles, CA 90066 July 29, 2024 Dear David: We are pleased to confirm our offer of employment with Armata Pharmaceuticals, Inc. (the “Company”) in the position of Senior Vice President, Finance, effective 16 August 2024, (the “Effective Date”) on the terms set forth in this letter agreement (the “Agreement”). 1. Position. |
|
| August 15, 2024 |
Exhibit 99.1 Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer LOS ANGELES, Calif., August 15, 2024 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics f |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Commi |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 ARMATA PHARMACEUTICAL |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| August 13, 2024 |
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update Exhibit 99.1 Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update LOS ANGELES, CA, August 13, 2024 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced fi |
|
| July 25, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 (this “ Amendment”) to the Employment Agreement (as defined below) is entered into as of July 22, 2024, by and between Armata Pharmaceuticals, Inc. (the “Company”) and Mina Pastagia, M.D. (the “Employee”). WHEREAS, the Company and the Employee are parties to that certain employment letter agreement, dated September 22, 2020 |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2024 |
Exhibit 10.2 4503 Glencoe Avenue Marina del Rey, CA 90292 Tel (310) 665-2928 · Fax (310) 665-2963 www.armatapharma.com September 22, 2020 Ms. Mina Pastagia, MD Dear Mina: We are pleased to confirm our offer of employment with Armata Pharmaceuticals, Inc. (the “Company”), in the position of Vice President, Clinical Development on the terms set forth in this letter agreement (the “Agreement”). 1. |
|
| June 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| May 7, 2024 |
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update LOS ANGELES, CA, May 7, 2024 - Armata Pharmaceuticals, Inc. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 ARMATA PHARMACEUTICA |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 22, 2024 |
Financial Statements and Exhibits, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| March 21, 2024 |
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update LOS ANGELES, CA, March 21, 2024 - Armata Pharmaceuticals, Inc. |
|
| March 21, 2024 |
Employment Agreement, dated August 30, 2023, by and between the Company and Richard Rychlik. Exhibit 10.28 Armata Pharmaceuticals, Inc. 4503 Glencoe Avenue Marina del Rey, CA 90292 August 30, 2023 Dear Richard: We are pleased to confirm our offer of employment with Armata Pharmaceuticals, Inc. (the “Company”) in the position of Vice President, Corporate Controller, effective September 5, 2023 (the “Effective Date”), on the terms set forth in this letter agreement (the “Agreement”). 1.Posi |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| March 21, 2024 |
Exhibit 21.1 Subsidiaries of Armata Pharmaceuticals, Inc. The following companies are direct or indirect wholly owned subsidiaries of Armata Pharmaceuticals, Inc.: Name Jurisdiction C3J Therapeutics, Inc. C3 Jian, LLC United States United States Biocontrol Limited United Kingdom AmpliPhi Australia Pty Ltd Australia Special Phage Holdings Pty Ltd Australia Special Phage Services Pty Ltd Australia |
|
| March 21, 2024 |
Exhibit 97 Execution Copy ARMATA PHARMACEUTICALS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1.Purpose. The purpose of this Policy is to describe the circumstances in which Executives will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. Each current and future Executive Officer shall be required to sign and return to the Compan |
|
| March 21, 2024 |
Description of the Company’s securities registered under Section 12 of the Exchange Act. Exhibit 4.9 DESCRIPTION OF COMMON STOCK The following description of our common stock, certain provisions of our articles of incorporation and bylaws, and certain provisions of Washington law are summaries. The following description is not complete and is subject to and qualified in its entirety by our articles of incorporation and bylaws. As of March 15, 2020, our articles of incorporation author |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-375 |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 ARMATA PHARMACEUTICALS, INC. |
|
| March 4, 2024 |
Exhibit 10.2 FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT, dated as of March 4, 2024 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “Guarantors” and, together with the Borrower, the “Loan Parties”) and |
|
| March 4, 2024 |
Exhibit 10.3 SECOND AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT SECOND AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT, dated as of March 4, 2024 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “Guarantors” and, together |
|
| March 4, 2024 |
Exhibit 99.1 Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva Proceeds to be used to continue to advance rigorously designed clinical trials of Armata’s high purity phage-based therapeutic candidates LOS ANGELES, Calif., March 4, 2024 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-spec |
|
| March 4, 2024 |
Exhibit 10.1 CREDIT AND SECURITY AGREEMENT Credit and Security Agreement, dated as of March 4, 2024, by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Subsidiary of the Borrower listed as a “Guarantor” on the signature pages hereto (together with each other Person that executes a joinder agreement and becomes a “Guarantor” hereunder or otherwise guarantees |
|
| March 4, 2024 |
ARMP / Armata Pharmaceuticals, Inc. / Innoviva, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-1097 Attention: Pavel Raifeld Chief Executiv |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 91-1549568 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5005 McConnell Avenue Los Angeles, CA 90066 (Address of P |
|
| January 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ARMATA PHARMACEUTICALS, INC. |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 91-1549568 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5005 McConnell Avenue Los Angeles, CA 90066 (Address of P |
|
| November 15, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ARMATA PHARMACEUTICALS, INC. |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| November 14, 2023 |
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update LOS ANGELES, Calif. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3754 |
|
| November 7, 2023 |
November 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D. |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 ARM |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| August 14, 2023 |
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update Exhibit 99.1 Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update LOS ANGELES, Calif., August 14, 2023 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial r |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 19, 2023 |
Exhibit 10.1 Execution Version SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this “Agreement”), delivered July 10, 2023, confirms the following understandings and agreements between Armata Pharmaceuticals, Inc. (the “Company”) and Brian Varnum (hereinafter referred to as “you” or “your”). In consideration of the promises set forth herein, you and the Company agr |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| July 11, 2023 |
ARMP / Armata Pharmaceuticals Inc / Innoviva, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-1097 Attention: Pavel Raifeld Chief Executive |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| July 11, 2023 |
Exhibit 10.4 July 10, 2023 Dr. Deborah Birx Via Email Re: Offer of Employment Dear Dr. Birx: We are pleased to confirm our offer of employment with Armata Pharmaceuticals, Inc. (the “Company” and together with its direct and indirect subsidiaries, the “Company Group”) in the position of Chief Executive Officer (“CEO”), effective as of the termination of employment of the Company Group’s current Ch |
|
| July 11, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT FIRST AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT, dated as of July 10, 2023 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time party to the Credit Agreement (as defined below) (the “Guarantors” and, together wi |
|
| July 11, 2023 |
Exhibit 10.1 CREDIT AND SECURITY AGREEMENT Credit and Security Agreement, dated as of July 10, 2023, by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Subsidiary of the Borrower listed as a “Guarantor” on the signature pages hereto (together with each other Person that executes a joinder agreement and becomes a “Guarantor” hereunder or otherwise guarantees |
|
| July 11, 2023 |
Exhibit 99.1 Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world-renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 - Armata Pharmaceuticals, Inc. (NYSE A |
|
| July 11, 2023 |
Exhibit 10.3 Amendment No. 1 to THE Second AMENDED AND RESTATED voting agreement This Amendment No. 1, dated as of July 10, 2023 (this “Amendment”), to the Second Amended and Restated Voting Agreement, dated as of February 9, 2022 (the “Voting Agreement”), is entered into by and among Armata Pharmaceuticals, Inc. (the “Company”), Innoviva, Inc. (“Innoviva”), and Innoviva Strategic Opportunities LL |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| May 12, 2023 |
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update Exhibit 99.1 Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update MARINA DEL REY, Calif., May 11, 2023 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial re |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 AR |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Commiss |
|
| April 6, 2023 |
ARMATA PHARMACEUTICALS, INC. 21,315,790 Shares of Common Stock 424B3 1 tm2311855d1424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) File No. 333-269726 PROSPECTUS ARMATA PHARMACEUTICALS, INC. 21,315,790 Shares of Common Stock This prospectus relates to the disposition from time to time of up to 21,315,790 shares of our common stock issuable upon conversion of a portion or all of the outstanding principal amount of, and any accrued and unpaid interest on, the l |
|
| April 5, 2023 |
ARMATA PHARMACEUTICALS, INC. 4503 Glencoe Avenue Marina del Rey, California 90292-3552 ARMATA PHARMACEUTICALS, INC. 4503 Glencoe Avenue Marina del Rey, California 90292-3552 April 5, 2023 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Armata Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-269726) (the “Registration Statement”) Dear Ladies and Gentlemen: Purs |
|
| March 28, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 28, 2023 As filed with the U.S. Securities and Exchange Commission on March 28, 2023 Registration No. 333-269726 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Washington 91-1549568 (State or Other Jurisdiction of (I.R.S. Employer Inco |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| March 16, 2023 |
Description of the Company’s securities registered under Section 12 of the Exchange Act. Exhibit 4.9 DESCRIPTION OF COMMON STOCK The following description of our common stock, certain provisions of our articles of incorporation and bylaws, and certain provisions of Washington law are summaries. The following description is not complete and is subject to and qualified in its entirety by our articles of incorporation and bylaws. As of March 15, 2020, our articles of incorporation author |
|
| March 16, 2023 |
Exhibit 99.1 Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update MARINA DEL REY, Calif., March 16, 2023 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today annou |
|
| March 16, 2023 |
Exhibit 21.1 Subsidiaries of Armata Pharmaceuticals, Inc. The following companies are direct or indirect wholly owned subsidiaries of Armata Pharmaceuticals, Inc.: Name Jurisdiction C3J Therapeutics, Inc. C3 Jian, LLC United States United States Biocontrol Limited United Kingdom AmpliPhi Australia Pty Ltd Australia Special Phage Holdings Pty Ltd Australia Special Phage Services Pty Ltd Australia |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-375 |
|
| March 6, 2023 |
February 22, 2023 NYSE American: ARMP CONFIDENTIAL Exhibit 99.2 February 22, 2023 NYSE American: ARMP CONFIDENTIAL 2 Forward Looking Statements This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All statements |
|
| March 6, 2023 |
Exhibit 99.1 Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis AP-PA02 is well-tolerated and data supports progression to Phase 2b Also announces first subject dosed in Phase 2 ‘Tailwind’ clinical trial of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) NCFB represents Arm |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2023 ARMATA PHARMACEUTICALS, INC. |
|
| February 13, 2023 |
Calculation of Filing Fees Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Armata Pharmaceuticals, Inc. |
|
| February 13, 2023 |
As filed with the U.S. Securities and Exchange Commission on February 13, 2023 As filed with the U.S. Securities and Exchange Commission on February 13, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Washington 91-1549568 (State or Other Jurisdiction of (I.R.S. Employer Incorpo |
|
| February 13, 2023 |
Exhibit 4.21 ARMATA PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 9, 2023, by and between Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”), and Innoviva Strategic Opportunities LLC, a Delaware limited liability company (the “Holder”). The Company and the Holder are referred to |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Co |
|
| January 10, 2023 |
ARMP / Armata Pharmaceuticals Inc / Innoviva, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm232849d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-1097 |
|
| January 10, 2023 |
EX-99.1 3 tm232848d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC MARINA DEL REY, Calif., January 10, 2023 – Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for a |
|
| January 10, 2023 |
Exhibit 10.1 Execution Version Secured Convertible Credit and Security Agreement Dated as of January 10, 2023 by and among ARMATA PHARMACEUTICALS, INC., as the Borrower, EACH SUBSIDIARY OF THE BORROWER HERETO FROM TIME TO TIME, as Guarantors, and INNOVIVA STRATEGIC OPPORTUNITIES LLC, as the Lender TABLE OF CONTENTS Page Article I DEFINITIONS; CERTAIN TERMS 1 Section 1.01 Definitions 1 Section 1.02 |
|
| December 19, 2022 |
Exhibit 10.1 Armata Pharmaceuticals, Inc. December 14, 2022 Todd R. Patrick 4503 Glencoe Avenue Marina del Rey, CA 90292 Dear Todd: The purpose of this letter agreement (this “Agreement”) is to amend that certain letter agreement by and between you and Armata Pharmaceuticals, Inc. (the “Company”), dated as of August 9, 2021 (the “Prior Agreement”) and to set forth the terms of your continued emplo |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (C |
|
| November 18, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2022 ARMATA PHARMACEUTICALS, INC. |
|
| November 9, 2022 |
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update Exhibit 99.1 Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update MARINA DEL REY, Calif., November 9, 2022 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (?Armata? or the ?Company?), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financia |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): Noveember 9, 2022 ARMATA PHARMACEUTICALS, INC. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 17, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy |
|
| September 20, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 20, 2022 ARMATA PHARMACEUTICALS, INC. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 ARMATA PHARMACEUTICALS, INC. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2022 |
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update Exhibit 99.1 Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update MARINA DEL REY, Calif., August 11, 2022 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (?Armata? or the ?Company?), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financia |
|
| June 1, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-264961 PROSPECTUS ARMATA PHARMACEUTICALS, INC. 13,500,000 Shares of Common Stock 4,500,000 Warrants to Purchase Common Stock This prospectus relates to the disposition from time to time of up to (i) 9,000,000 shares of our common stock, $0.01 par value per share, (ii) warrants to purchase 4,500,000 shares of our common stock (the ?Warrants?), a |
|
| May 26, 2022 |
ARMATA PHARMACEUTICALS, INC. 4503 Glencoe Avenue Marina del Rey, California 90292-3552 ARMATA PHARMACEUTICALS, INC. 4503 Glencoe Avenue Marina del Rey, California 90292-3552 May 26, 2022 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Armata Pharmaceuticals, Inc. (the ?Company?) Registration Statement on Form S-3 (File No. 333-264961) (the ?Registration Statement?) Dear Ladies and Gentlemen: Pursu |
|
| May 24, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 23, 2022 S-3/A 1 tm2215582d2s3a.htm FORM S-3/A As filed with the U.S. Securities and Exchange Commission on May 23, 2022 Registration No. 333-264961 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Washington 91-154956 |
|
| May 16, 2022 |
Calculation of Filing Fees Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Armata Pharmaceuticals, Inc. |
|
| May 16, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 13, 2022 As filed with the U.S. Securities and Exchange Commission on May 13, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Washington 91-1549568 (State or Other Jurisdiction of (I.R.S. Employer Incorporatio |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 AR |
|
| April 6, 2022 |
ARMATA PHARMACEUTICALS, INC. 2,121,213 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-263936 PROSPECTUS ARMATA PHARMACEUTICALS, INC. 2,121,213 Shares of Common Stock This prospectus relates to the disposition from time to time of up to 2,121,213 shares of our common stock, $0.01 par value per share, that were initially issued pursuant to the Securities Purchase Agreement dated as of October 28, 2021 (the ?Securities Purchase Agr |
|
| April 5, 2022 |
ARMATA PHARMACEUTICALS, INC. 4503 Glencoe Avenue Marina del Rey, California 90292-3552 ARMATA PHARMACEUTICALS, INC. 4503 Glencoe Avenue Marina del Rey, California 90292-3552 April 5, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Armata Pharmaceuticals, Inc. (the ?Company?) Registration Statement on Form S-3 (File No. 333-263936) (the ?Registration Statement?) Dear Ladies and Gentlemen: Pursuant |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-1097 Attention: Pavel Raifeld Chief Executive |
|
| March 31, 2022 |
Exhibit 99.1 Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva MARINA DEL REY, Calif., March 31, 2022 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (?Armata? or the ?Company?), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2022 ARMATA PHARMACEUTICALS, INC. |
|
| March 29, 2022 |
Calculation of Filing Fees Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Armata Pharmaceuticals, Inc. |
|
| March 29, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 29, 2022 As filed with the U.S. Securities and Exchange Commission on March 29, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Washington 91-1549568 (State or Other Jurisdiction of (I.R.S. Employer Incorporat |
|
| March 28, 2022 |
Employment Agreement, dated March 28, 2022, between the Company and Ms. Butler. Exhibit 10.2 March 28, 2022 Erin Butler 4503 Glencoe Avenue Marina del Rey, CA 90292 Dear Erin: We are pleased to confirm our offer of continued employment with Armata Pharmaceuticals, Inc. (the ?Company?) in the position of Vice President of Finance and Administration, effective April 1, 2022, on the terms set forth in this letter agreement (the ?Agreement?). 1. Position. As Vice President of Fin |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2022 ARMATA PHARMACEUTICALS, INC. |
|
| March 28, 2022 |
Exhibit 10.1 March 28, 2022 Steve R. Martin 4503 Glencoe Avenue Marina del Rey, CA 90292 Dear Steve: This agreement (this ?Agreement?) replaces and supersedes the offer letter agreement between you and Armata Pharmaceuticals, Inc. (f/k/a AmpliPhi Biosciences Corporation) (the ?Company?) dated January 18, 2016, as amended on April 1, 2017 (the ?Prior Agreement?) and sets forth the terms of your con |
|
| March 17, 2022 |
Exhibit 21.1 ? Subsidiaries of Armata Pharmaceuticals, Inc. ? The following companies are direct or indirect wholly owned subsidiaries of Armata Pharmaceuticals, Inc.: ? ? ? ? Name Jurisdiction C3J Therapeutics, Inc. C3 Jian, LLC ? United States United States Biocontrol Limited ? United Kingdom AmpliPhi Australia Pty Ltd ? Australia Special Phage Holdings Pty Ltd ? Australia Special Phage Services |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-375 |
|
| March 17, 2022 |
Description of the Company’s securities registered under Section 12 of the Exchange Act. Exhibit 4.9 ? DESCRIPTION OF COMMON STOCK ? The following description of our common stock, certain provisions of our articles of incorporation and bylaws, and certain provisions of Washington law are summaries. The following description is not complete and is subject to and qualified in its entirety by our articles of incorporation and bylaws. ? As of March 15, 2020, our articles of incorporation |
|
| March 9, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive P |
|
| February 24, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive P |
|
| February 11, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this ?Agreement?), dated as of February 9, 2022, is made by and between (i) Armata Pharmaceuticals, Inc., a Washington corpora |
|
| February 11, 2022 |
Exhibit 99.1 Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company?s Bacteriophage Development MARINA DEL REY, Calif., February 9, 2022 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (?Armata? or the ?Company?), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infe |
|
| February 11, 2022 |
Exhibit 10.2 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of February 9, 2022 by and between Armata Pharmaceuticals Inc., a Washington corporation (the ?Company?), Innoviva, Inc., a Delaware corporation (?Innoviva?), and Innoviva Strategic Opportunities LLC, a Delaware limited liability company and |
|
| February 11, 2022 |
Exhibit 10.3 ARMATA PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of February 9, 2022, by and between Armata Pharmaceuticals, Inc., a Washington corporation (the ?Company?), and Innoviva Strategic Opportunities LLC, a Delaware limited liability company (the ?Holder?). The Company and the Holder are referred to |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2022 ARMATA PHARMACEUTICALS, INC. |
|
| February 11, 2022 |
SC 13D/A 1 i50535136.htm SCHEDULE 13D/A (AMENDMENT NO. 6) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame |
|
| February 11, 2022 |
Exhibit 4.1 THE WARRANTS REPRESENTED BY THIS WARRANT CERTIFICATE ARE TRANSFERABLE AND ASSIGNABLE SUBJECT TO COMPLIANCE WITH APPLICABLE SECURITIES LAWS. THE WARRANTS REPRESENTED BY THIS WARRANT CERTIFICATE WILL BE VOID AND OF NO VALUE UNLESS EXERCISED ON OR BEFORE 5:00 P.M. (NEW YORK TIME) ON [?], 2027. WARRANT CERTIFICATE ARMATA PHARMACEUTICALS, Inc. (Incorporated under the Laws of the State of Wa |
|
| February 11, 2022 |
Exhibit 10.4 SECOND AMENDED AND RESTATED VOTING AGREEMENT This SECOND AMENDED AND RESTATED VOTING AGREEMENT (this ?Agreement?) is made and entered into as of February 9, 2022 (the ?Effective Date?), by and among Armata Pharmaceuticals Inc., a Washington corporation (the ?Company?), Innoviva, Inc., a Delaware corporation (?Innoviva?), and Innoviva Strategic Opportunities LLC, a Delaware limited lia |
|
| January 5, 2022 |
Exhibit 99.1 Brian Varnum, Chief Executive Officer Steve Martin, Chief Financial Officer January 5, 2022 NYSE American: ARMP 2 Forward Looking Statements This presentation contains ?forward - looking? statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or |
|
| January 5, 2022 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Com |
|
| January 5, 2022 |
Exhibit 99.2 Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs Enhanced AP-PA02 enters SWARM-P.a. study AP-PA02 identified as lead cocktail for non-cystic fibrosis bronchiectasis Phase 2 trial Distinct phage cocktail (AP-PA03) for pneumonia advances to manufacturing MARINA DEL REY, California, January 5, 2022 ? Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (?Armata,? |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 2, 2021 |
Exhibit 99.1 Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility 56,000 square foot facility in Los Angeles enables a substantial increase in manufacturing scale and capacity to support Armata?s advancing pipeline MARINA DEL REY, California, November 02, 2021 ? Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (?Armata,? ?us,? ?our,? or the ?Company?), a biotechnology |
|
| November 2, 2021 |
Exhibit 10.1 OFFICE LEASE LANDLORD: 5005 MCCONNELL AVENUE, LLC, a Delaware limited liability company TENANT: ARMATA PHARMACEUTICALS, INC., a Washington corporation -1- TABLE OF CONTENTS Page 1. Premises 1 2. Term 1 3. Rent 2 4. Operating Expenses; Real Property Taxes and Assessments; Insurance Costs and Utilities Costs 2 5. Security Deposit; Letter of Credit 4 6. Use 6 7. Payments and Notices 8 8. |
|
| November 2, 2021 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 ARMATA PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Co |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Pavel Raifeld Chief Executive Officer Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-1097 (N |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 28, 2021 ARMATA PHARMACEUTICALS, INC. |
|
| October 29, 2021 |
Exhibit 10.3 AMENDED AND RESTATED VOTING AGREEMENT This AMENDED AND RESTATED VOTING AGREEMENT (this ?Agreement?) is made and entered into as of October 28, 2021 (the ?Effective Date?), by and between Armata Pharmaceuticals Inc., a Washington corporation (the ?Company?), Innoviva, Inc., a Delaware corporation (?Innoviva?) and Innoviva Strategic Opportunities LLC (a Delaware limited liability compan |
|
| October 29, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this ?Agreement?), dated as of October 28, 2021, is made by and among (i) Armata Pharmaceuticals, Inc., a Washington corporati |
|
| October 29, 2021 |
Exhibit 10.2 ARMATA PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of October 28, 2021, by and between Armata Pharmaceuticals, Inc., a Washington corporation (the ?Company?), Innoviva Strategic Opportunities LLC (?Innoviva?) and Cystic Fibrosis Foundation, a Delaware corporation (?CFF? and together with Innoviva |
|
| October 29, 2021 |
Exhibit 99.1 Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals Funds to be used to further advance development of lead candidate AP-PA02, which is being evaluated in a Phase 1b/2a clinical trial in Pseudomonas aeruginosa respiratory infections in CF patients Innoviva, a significant Armata shareholder, also elected to participate MARINA DEL REY, California, October 28, 20 |
|
| August 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2021 ARMATA PHARMACEUTICALS, INC. |
|
| August 13, 2021 |
Exhibit 99.1 Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update Continues to advance AP-PA02 through Phase 1b/2a clinical trial as a potential treatment for cystic fibrosis patients with chronic Pseudomonas aeruginosa Announced that Todd R. Patrick, CEO, has retired from the Company. Brian Varnum, PhD, former President and Chief Development Officer, has b |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 12, 2021 |
Exhibit 10.23 August 9, 2021 Todd Patrick 4503 Glencoe Avenue Marina del Rey, CA 90292 Dear Todd: This letter amends the agreement between you and C3J Therapeutics, Inc. dated October 1, 2018, as amended (the ?Prior Agreement? and, together with this letter, the ?Agreement?), to set forth the terms of your continued employment with Armata Pharmaceuticals, Inc. (the ?Company?) in connection with yo |
|
| August 12, 2021 |
? Exhibit 10.22 August 1, 2021 Brian Varnum, Ph.D. 4503 Glencoe Avenue Marina del Rey, CA 90292 Dear Brian: We are pleased to confirm our offer of continued employment with Armata Pharmaceuticals, Inc. (the ?Company?) in the position of Chief Executive Officer (?CEO?) on the terms set forth in this letter agreement (the ?Agreement?). 1. Position. As CEO, you will be responsible for managing the da |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2021 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other jurisdiction of incorporation) (Commi |
|
| June 14, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2021 ARMATA PHARMACEUTICALS, INC. |
|
| May 20, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-256104 PROSPECTUS ARMATA PHARMACEUTICALS, INC. 12,307,694 Shares of Common Stock 6,153,847 Warrants to Purchase Common Stock This prospectus relates to the disposition from time to time of up to (i) 6,153,847 shares of our common stock, $0.01 par value per share, (ii) warrants to purchase 6,153,847 shares of our common stock (the ?Warrants?), a |
|
| May 18, 2021 |
May 18, 2021 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Armata Pharmaceuticals, Inc. |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 ARMATA PHARMACEUTICALS, INC. |
|
| May 14, 2021 |
EX-99.1 2 tm2116541d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update Company earns $750,000 milestone payment related to SWARM-P.a. Study MARINA DEL REY, Calif., May 13, 2021 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacterio |
|
| May 13, 2021 |
As filed with the U.S. Securities and Exchange Commission on May 13, 2021 As filed with the U.S. Securities and Exchange Commission on May 13, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARMATA PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Washington 91-1549568 (State or Other Jurisdiction of (I.R.S. Employer Incorporatio |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 21, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive P |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Pavel Raifeld Chief Executive Officer Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-1097 (N |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2021 ARMATA PHARMACEUTICALS, INC. |
|
| March 18, 2021 |
EX-21.1 3 armp-20201231ex21148ae91.htm EX-21.1 Exhibit 21.1 Subsidiaries of Armata Pharmaceuticals, Inc. The following companies are direct or indirect wholly owned subsidiaries of Armata Pharmaceuticals, Inc.: Name Jurisdiction C3J Therapeutics, Inc. C3 Jian, LLC United States United States Biocontrol Limited United Kingdom AmpliPhi Australia Pty Ltd Australia Special Phage Holdings Pty Ltd Austr |
|
| March 18, 2021 |
Description of the Company’s securities registered under Section 12 of the Exchange Act. Exhibit 4.9 ? DESCRIPTION OF COMMON STOCK ? The following description of our common stock, certain provisions of our articles of incorporation and bylaws, and certain provisions of Washington law are summaries. The following description is not complete and is subject to and qualified in its entirety by our articles of incorporation and bylaws. ? As of March 15, 2020, our articles of incorporation |
|
| March 18, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2021 ARMATA PHARMACEUTICALS, INC. |
|
| March 17, 2021 |
Exhibit 99.1 Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva MARINA DEL REY, California, March 17, 2021 ? Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (?Armata? or the ?Company?), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infectio |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Pavel Raifeld Chief Executive Officer Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-1097 (N |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) xDefinitive Proxy Statemen |
|
| February 22, 2021 |
February 22, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: xPreliminary Proxy Statement ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨Definitive Proxy Statemen |
|
| January 27, 2021 |
EX-10.3 5 tm214248d1ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 ARMATA PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 26, 2021, by and between Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”), and Innoviva Strategic Opportunities LLC (the “Holder”). The Company and the Holder are referr |
|
| January 27, 2021 |
EX-10.4 6 tm214248d1ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”) is made and entered into as of January 26, 2021 (the “Effective Date”), by and between Armata Pharmaceuticals Inc., a Washington corporation (the “Company”), Innoviva, Inc., a Delaware corporation (“Innoviva”) and Innoviva Strategic Opportunities LLC (a Delaware limited liability comp |
|
| January 27, 2021 |
EX-99.1 7 tm214248d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’s Bacteriophage Development Programs MARINA DEL REY, California, January 27, 2021 – Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for a |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2021 ARMATA PHARMACEUTICALS, INC. |
|
| January 27, 2021 |
EX-10.2 4 tm214248d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This AMENDED AND INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of January 26, 2021 by and between Armata Pharmaceuticals Inc., a Washington corporation (the “Company”), Innoviva, Inc., a Delaware corporation (“Innoviva”), and Innoviva Strategic Opportunities LLC, a Del |
|
| January 27, 2021 |
EX-99.1 2 i40476268b.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d−1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Armata Pharmaceuticals, Inc. and further agree that |
|
| January 27, 2021 |
Exhibit 4.1 THE WARRANTS REPRESENTED BY THIS WARRANT CERTIFICATE ARE TRANSFERABLE AND ASSIGNABLE SUBJECT TO COMPLIANCE WITH APPLICABLE SECURITIES LAWS. THE WARRANTS REPRESENTED BY THIS WARRANT CERTIFICATE WILL BE VOID AND OF NO VALUE UNLESS EXERCISED ON OR BEFORE 5:00 P.M. (NEW YORK TIME) ON []1. WARRANT CERTIFICATE ARMATA PHARMACEUTICALS, Inc. (Incorporated under the Laws of the State of Washingt |
|
| January 27, 2021 |
EX-10.1 3 tm214248d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of January 26, 2021, is made by and between (i) Armata |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Pavel Raifeld Chief Executive Officer Innoviva, Inc. 1350 Old Bayshore Highway Suite 400 Burlingame, CA 877-202-1097 (N |
|
| January 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2021 ARMATA PHARMACEUTICALS, INC. |
|
| January 6, 2021 |
EX-99.1 2 tm211933d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer January 6, 2021 NYSE American: ARMP 2 I This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions pr |
|
| December 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2020 ARMATA PHARMACEUTICALS, INC. |
|
| December 9, 2020 |
Exhibit 99.1 Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors Biogen Chief Accounting Officer adds significant financial leadership experience MARINA DEL REY, California, December 9, 2020 – Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for ant |
|
| November 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3754 |
|
| November 12, 2020 |
As filed with the Securities and Exchange Commission on November 12, 2020 Registration No. |
|
| November 12, 2020 |
Exhibit 99.1 ARMATA PHARMACEUTICALS, INC. Restricted Stock Unit Grant Notice (INDUCEMENT GRANT OUTSIDE OF 2016 EQUITY INCENTIVE PLAN) As a material inducement for Participant to commence employment with Armata Pharmaceuticals, Inc. (the “Company”), the Company hereby grants to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units” |
|
| October 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| October 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 13, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37544 ARM |
|
| June 18, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2020 ARMATA PHARMACEUTICALS, INC. |
|
| June 18, 2020 |
EX-99.1 2 tm2022924d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections Non-dilutive funding to be used to advance the company's second phage-based therapeutic candidate in a Phase 1b/2 clinical study MARINA DEL REY, Calif., June 17, 2020 |
|
| May 14, 2020 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Execution Copy March 10, 2020 Todd R. Patrick Chief Executive Officer Armata Pharmaceuticals, Inc. 4503 Glencoe Avenue Manner del Rey, California 90292 Development Program: Test the Saf |
|
| May 14, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001‑37544 AR |
|
| May 14, 2020 |
Exhibit 10.3 ASSIGNMENT AND FIRST AMENDMENT OF OFFICE LEASE This Assignment and First Amendment of Office Lease (“Amendment”) is made and entered into as of this, the day of April, 2020 (the “Effective Date”) in the City of Los Angeles, County of Los Angeles, State of California, by and among MARINA BUSINESS CENTER, LLC, a California limited liability company, hereafter called “Landlord”, C3 JIAN, |
|
| May 14, 2020 |
EX-10.2 3 armp-20200331ex1026b8e32.htm EX-10.2 Exhibit 10.2 January 18, 2012 Dr. Brian Clark Varnum Santa Monica, CA 90402 Re: Employment Agreement Dear Brian: On behalf of C3 Jian, Inc. (the "Company"), I am pleased to confirm our verbal offer of employment to you for the position of Vice President, Product Development, reporting to the Chief Executive Officer. This letter sets out the terms of y |
|
| April 28, 2020 |
Exhibit 99.1 Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer April 28, 2020 NYSE American: ARMP 2 I This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materia |
|
| April 28, 2020 |
Exhibit 99.2 Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector MARINA DEL REY, California, April 28, 2020 – Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infectio |
|
| April 28, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 tm2017816d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2020 ARMATA PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other juris |
|
| April 9, 2020 |
Common Stock Preferred Stock Debt Securities 424B3 1 tm2015402-2424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-237534 PROSPECTUS $100,000,000 Common Stock Preferred Stock Debt Securities Warrants Units From time to time, we may sell up to an aggregate of $100,000,000 of our common stock, preferred stock, debt securities, warrants or units in any combination of the foregoing, in amounts, at prices and on terms described |
|
| April 9, 2020 |
ARMATA PHARMACEUTICALS, INC. 17,421,600 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237533 PROSPECTUS ARMATA PHARMACEUTICALS, INC. 17,421,600 Shares of Common Stock This prospectus relates to the disposition from time to time of up to (i) 8,710,800 shares of our common stock, $0.001 par value per share, and (ii) 8,710,800 shares of our common stock issuable upon exercise of the warrants for purchase of common stock (the “Warra |
|
| April 6, 2020 |
April 6, 2020 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Armata Pharmaceuticals, Inc. |
|
| April 6, 2020 |
CORRESP 1 filename1.htm April 6, 2020 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Armata Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-237533) (the “Registration Statement”) Dear Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Sec |
|
| April 1, 2020 |
ARMP / Armata Pharmaceuticals, Inc. S-3 - - FORM S-3 As filed with the Securities and Exchange Commission on April 1, 2020 Registration No. |
|
| April 1, 2020 |
Exhibit 4.2 Form of Indenture ARMATA PHARMACEUTICALS, INC. as ISSUER and As INDENTURE TRUSTEE INDENTURE Dated as of , 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 3 Section 1.01 Definitions. 3 Section 1.02 Other Definitions. 7 Section 1.03 Incorporation by Reference of Trust Indenture Act. 7 Section 1.04 Rules of Construction. 8 ARTICLE II TILE SECURITIES 8 Section 2.01 |
|
| April 1, 2020 |
ARMP / Armata Pharmaceuticals, Inc. S-3 - - FORM S-3 As filed with the U.S. Securities and Exchange Commission on April 1, 2020 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Armata Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Washington 91-1549568 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or |
|
| March 31, 2020 |
ARMP / Armata Pharmaceuticals, Inc. / Innoviva, Inc. - SCHEDULE 13D/A, #1 Activist Investment SC 13D/A 1 i33953321.htm SCHEDULE 13D/A, #1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARMATA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04216R 102 (CUSIP Number) Geoffrey Hulme Interim Principal Executive Officer Innoviva, Inc. 1350 Old |
|
| March 30, 2020 |
Exhibit 99.1 Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. · Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02 MARINA DEL REY, California, March 30, 2020 – Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely ta |
|
| March 30, 2020 |
Exhibit 3.1 ARTICLES OF AMENDMENT OF ARMATA PHARMACEUTICALS, INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION Pursuant to Chapter 23B.10 of the Washington Business Corporation Act (the “WBCA”), Armata Pharmaceuticals, Inc., a Washington corporation, hereby submits the following Articles of Amendment to its Amended and Restated Articles of Incorporation (the “Articles of Amendment”): Article 1. |
|
| March 30, 2020 |
8-K 1 tm2014179d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2020 ARMATA PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Washington 001-37544 91-1549568 (State or other juris |
